AR092354A1 - Derivados de carbamato/urea - Google Patents

Derivados de carbamato/urea

Info

Publication number
AR092354A1
AR092354A1 ARP130102583A ARP130102583A AR092354A1 AR 092354 A1 AR092354 A1 AR 092354A1 AR P130102583 A ARP130102583 A AR P130102583A AR P130102583 A ARP130102583 A AR P130102583A AR 092354 A1 AR092354 A1 AR 092354A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
halogen
amino
once
Prior art date
Application number
ARP130102583A
Other languages
English (en)
Spanish (es)
Inventor
Jiang Haiyang
J Troxler Thomas
Wang Tielin
Curzi Marco
Wang Xiaoyang
Kay Dodd Stephanie
Gary Bock Marck
Auberson Yves
Braga Dario
Karpinski Piotr
Luca Giaffreda Stefano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092354(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR092354A1 publication Critical patent/AR092354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP130102583A 2012-07-20 2013-07-22 Derivados de carbamato/urea AR092354A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28

Publications (1)

Publication Number Publication Date
AR092354A1 true AR092354A1 (es) 2015-04-15

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102583A AR092354A1 (es) 2012-07-20 2013-07-22 Derivados de carbamato/urea

Country Status (41)

Country Link
US (4) US9034874B2 (enExample)
EP (1) EP2875016B1 (enExample)
JP (1) JP6203841B2 (enExample)
KR (1) KR102150739B1 (enExample)
CN (1) CN104470911B (enExample)
AP (1) AP3710A (enExample)
AR (1) AR092354A1 (enExample)
AU (1) AU2013291617B2 (enExample)
BR (1) BR112015001207B1 (enExample)
CA (1) CA2878006C (enExample)
CL (1) CL2015000056A1 (enExample)
CO (1) CO7170173A2 (enExample)
CR (1) CR20150019A (enExample)
CU (1) CU24248B1 (enExample)
CY (1) CY1119492T1 (enExample)
DK (1) DK2875016T3 (enExample)
EA (1) EA026091B1 (enExample)
ES (1) ES2648512T3 (enExample)
GT (1) GT201500012A (enExample)
HR (1) HRP20171692T1 (enExample)
HU (1) HUE035592T2 (enExample)
IL (1) IL236656A (enExample)
IN (1) IN2014DN10449A (enExample)
JO (1) JO3439B1 (enExample)
LT (1) LT2875016T (enExample)
MX (1) MX362059B (enExample)
MY (1) MY168752A (enExample)
NO (1) NO2875016T3 (enExample)
NZ (1) NZ702346A (enExample)
PE (1) PE20151155A1 (enExample)
PH (1) PH12014502743B1 (enExample)
PL (1) PL2875016T3 (enExample)
PT (1) PT2875016T (enExample)
RS (1) RS56479B1 (enExample)
SG (2) SG11201408020RA (enExample)
SI (1) SI2875016T1 (enExample)
TN (1) TN2014000497A1 (enExample)
TW (1) TWI597276B (enExample)
UY (1) UY34921A (enExample)
WO (1) WO2014013469A1 (enExample)
ZA (1) ZA201408805B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) * 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN112789038A (zh) 2018-10-11 2021-05-11 诺华股份有限公司 H3r反向激动剂用于治疗与帕金森病(pd)相关的日间过度嗜睡的用途
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (enExample) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
JP4522651B2 (ja) 2001-03-13 2010-08-11 シェーリング コーポレイション 新規非イミダゾール化合物
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
KR20090102883A (ko) 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
WO2006029056A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063934A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US8093248B2 (en) * 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
JP5677325B2 (ja) 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
TN2014000497A1 (en) 2016-03-30
MX2015000903A (es) 2015-04-10
MX362059B (es) 2019-01-07
IL236656A (en) 2017-12-31
IL236656A0 (en) 2015-02-26
CL2015000056A1 (es) 2015-03-20
PH12014502743A1 (en) 2015-02-02
CN104470911B (zh) 2018-04-06
MY168752A (en) 2018-11-30
PH12014502743B1 (en) 2015-02-02
CY1119492T1 (el) 2018-03-07
AP2014008109A0 (en) 2014-12-31
JP6203841B2 (ja) 2017-09-27
HRP20171692T1 (hr) 2017-12-15
JO3439B1 (ar) 2019-10-20
CA2878006A1 (en) 2014-01-23
TWI597276B (zh) 2017-09-01
US9273026B2 (en) 2016-03-01
AU2013291617A1 (en) 2015-01-15
PE20151155A1 (es) 2015-08-05
BR112015001207A8 (pt) 2018-01-16
HUE035592T2 (en) 2018-05-28
NZ702346A (en) 2017-06-30
CA2878006C (en) 2020-10-27
US9624192B2 (en) 2017-04-18
KR102150739B1 (ko) 2020-09-02
IN2014DN10449A (enExample) 2015-08-21
US9034874B2 (en) 2015-05-19
PL2875016T3 (pl) 2018-01-31
ZA201408805B (en) 2016-08-31
CR20150019A (es) 2015-05-04
CO7170173A2 (es) 2015-01-28
US20170275264A1 (en) 2017-09-28
US20140163036A1 (en) 2014-06-12
AU2013291617B2 (en) 2015-10-01
PT2875016T (pt) 2017-11-30
US20160244426A1 (en) 2016-08-25
RS56479B1 (sr) 2018-01-31
GT201500012A (es) 2017-11-09
EP2875016B1 (en) 2017-08-23
BR112015001207A2 (pt) 2017-08-01
EP2875016A1 (en) 2015-05-27
US20150218127A1 (en) 2015-08-06
UY34921A (es) 2014-02-28
KR20150036081A (ko) 2015-04-07
EA026091B1 (ru) 2017-02-28
EA201590250A1 (ru) 2015-05-29
ES2648512T3 (es) 2018-01-03
SI2875016T1 (sl) 2017-11-30
HK1204609A1 (en) 2015-11-27
LT2875016T (lt) 2017-11-10
CU24248B1 (es) 2017-02-02
NO2875016T3 (enExample) 2018-01-20
BR112015001207B1 (pt) 2022-08-09
WO2014013469A1 (en) 2014-01-23
CU20150006A7 (es) 2016-02-29
SG11201408020RA (en) 2015-03-30
JP2015522606A (ja) 2015-08-06
DK2875016T3 (da) 2017-11-27
TW201408656A (zh) 2014-03-01
CN104470911A (zh) 2015-03-25
SG10201700188PA (en) 2017-02-27
AP3710A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
AR124607A2 (es) Arilquinazolinas
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR115885A1 (es) Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR112687A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción tricíclica, conjugados de estos y métodos y usos de estos
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR092293A1 (es) Amidas de acido n-(1,2,5-oxadiazol-3-il)-, n-(1,3,4-oxadiazol-2-il)-, n-(tetrazol-5-il)- y n-(triazol-5-il)-arilcarboxilico y su uso como herbicidas
ECSP11011200A (es) Derivados de oxadiazale como agonista de los receptores s1p1
AR086318A1 (es) Piridil aminopiridinas como inhibidores de syk
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR094312A1 (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
AR090076A1 (es) Metodos para producir compuestos sulfilimina
AR104326A1 (es) Compuestos nucleósidos 5-sustituidos
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR107738A1 (es) Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas
CR20150661A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR106047A1 (es) Derivado de biarilo y medicamento que contiene el mismo para el tratamiento de infecciones fúngicas
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
PE20151155A1 (es) Derivados de carbamato/urea
PE20150598A1 (es) Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1
AR095350A1 (es) Compuestos inhibidores de una histona deacetilasa y composición farmacéutica que los contiene
PE20160880A1 (es) Compuestos de triazolona y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration